Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 25, 1377 (1 December 2007) | doi:10.1038/nbt1207-1377
Ian Frazer
Abstract
The commercial approval in June 2006 of the first HPV vaccine, Gardasil (recombinant HPV subtypes 6/11/16/18), marketed by Whitehouse Station, New Jersey–based Merck, has enabled Ian Frazer to raise awareness about the potential to eradicate cervical cancer. But his increased visibility—he was named Australian Man of the Year in 2006—and 20/20 hindsight have also given him the forum and voice to advocate for more effective ways to build public-private partnerships.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
